ADC Collaborations

There are nearly 20 collaborator ADC programs in clinical development using our technology.

Learn more

ADC Technology

Our pipeline of empowered antibody-based product candidates is based primarily on our ADC technology.

Learn more

A diversified product pipeline

We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our robust pipeline of empowered antibody-based therapies is designed to address significant unmet medical needs.

Program Therapeutic Area Preclinical Phase 1 Phase 2 Pivotal/ Phase 3 Approved
ADCETRIS® (brentuximab vedotin)
Relapsed Hodgkin lymphoma (HL)
Relapsed systemic anaplastic large cell lymphoma
Post-transplant HL consolidation
Brentuximab Vedotin
ALCANZA: Relapsed CD30+ cutaneous T-cell lymphoma
ECHELON-1: Frontline HL
(+ chemotherapy)
ECHELON-2: Frontline CD30+ mature T-cell lymphoma (+ chemo)
Frontline HL in patients 60+ (+/− other agents)
Frontline CD30+ DLBCL
(+ RCHP)
Relapsed CD30+ DLBCL (Rituxan + bendamustine +/− BV) (Planned)
Systemic lupus erythematosus
Relapsed HL, NHL
(+ nivolumab) (Planned)
Relapsed DLBCL (R-ICE +/− SGN-CD19A) (Planned)
Relapsed ALL, NHL
Relapsed AML
Frontline AML (single agent and combinations)
Relapsed breast cancer
Relapsed NHL, renal cell carcinoma
Relapsed solid tumors
Relapsed bladder cancer
Relapsed solid tumors

*Co-development program with Agensys, an affiliate of Astellas
**Non-fucosylated antibody empowered with our SEA technology, resulting in a novel immuno-oncology agent

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave